About Prelude Therapeutics
Prelude Therapeutics is a company based in Philadelphia (United States) founded in 2016 by Kris Vaddi. It operates as a HealthTech. Prelude Therapeutics has raised $145 million across 4 funding rounds from investors including Fidelity Investments and Orbimed. The company has 131 employees as of December 31, 2024. Prelude Therapeutics offers products and services including SMARCA2 Degraders, KAT6A Degraders, Precision ADCs, and CDK Inhibitors. Prelude Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others.
- Headquarter Philadelphia, United States
- Employees 131 as on 31 Dec, 2024
- Founders Kris Vaddi
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Prelude Therapeutics Incorporated
-
Annual Revenue
$7 M (USD)0as on Dec 31, 2024
-
Net Profit
-$127.17 M (USD)-4.38as on Dec 31, 2024
-
EBITDA
-$137.94 M (USD)-5.21as on Dec 31, 2024
-
Total Equity Funding
$145 M (USD)
in 4 rounds
-
Latest Funding Round
$50 M (USD), Series C
Aug 24, 2020
-
Investors
Fidelity Investments
& 1 more
-
Employee Count
131
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Prelude Therapeutics
Prelude Therapeutics is a publicly listed company on the NASDAQ with ticker symbol PRLD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Prelude Therapeutics
Prelude Therapeutics offers a comprehensive portfolio of products and services, including SMARCA2 Degraders, KAT6A Degraders, Precision ADCs, and CDK Inhibitors.
SMARCA2 degraders are developed for cancer treatment efficacy.
KAT6A degraders are designed for breast cancer treatment.
Precision ADCs are created for targeted cancer therapy.
CDK inhibitors are formulated for various cancer treatments.
People of Prelude Therapeutics
Unlock access to complete
Funding Insights of Prelude Therapeutics
Prelude Therapeutics has successfully raised a total of $145M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $50 million completed in August 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Prelude Therapeutics
Prelude Therapeutics has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
Provider of brokerage accounts, retirement planning, wealth management, and trading platforms
|
Locked | Locked | Locked |
Investor details for Prelude Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Prelude Therapeutics
Investment portfolio details for Prelude Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Prelude Therapeutics
Detailed financials for Prelude Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Prelude Therapeutics Comparisons
Peer comparison for Prelude Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Prelude Therapeutics
Prelude Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
Selective kinase inhibitors are developed for genomically defined cancers.
|
|
| Locked | Locked | Locked |
Targeted therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
Detailed competitors of Prelude Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Prelude Therapeutics
Complete news archive for Prelude Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Prelude Therapeutics
Prelude Therapeutics was founded in 2016.
Prelude Therapeutics is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Kris Vaddi is the current CEO of Prelude Therapeutics. They have also founded this company.
Prelude Therapeutics is a funded company, having raised a total of $145M across 4 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Prelude Therapeutics is 131.
Annual revenue of Prelude Therapeutics is $7M as on Dec 31, 2024.
Prelude Therapeutics is engaged in the discovery and development of innovative cancer medicines. The company specializes in precision oncology, targeting high unmet needs with novel drug candidates. Programs include first-in-class SMARCA2 and KAT6A degraders, alongside precision antibody-drug conjugates (ADCs). Their expertise in targeted protein degradation is leveraged to advance next-generation therapies. Collaborations with partners like AbCellera enhance their ADC development. The focus remains on extending precision medicine benefits to cancer patients across various tumor types and resistance mechanisms.
Prelude Therapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and argenx.
Prelude Therapeutics offers SMARCA2 Degraders, KAT6A Degraders, Precision ADCs, and CDK Inhibitors.
Yes, Prelude Therapeutics is publicly traded on NASDAQ under the ticker symbol PRLD.
Prelude Therapeutics has 2 investors. Key investors include Fidelity Investments, and Orbimed.
The ticker symbol of Prelude Therapeutics is PRLD on NASDAQ.